Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.40 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25502011 | 0.92 | HSD11B1 (0.51) | HSD11B1SMN1; SMN2HRH3KMT2AALDH1A1 | |
| SCHEMBL10119970 | 0.82 | CHRNB2 (0.50) | HSD11B1HRH3CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL26790076 | 0.81 | HTT (0.46) | HSD11B1SMN1; SMN2HRH3CHRNB2CHRNA3 | |
| SCHEMBL27051242 | 0.81 | WNT1 (0.41) | HSD11B1SMN1; SMN2HRH3KMT2ACHRNB2 | |
| SCHEMBL25480271 | 0.80 | HRH3 (0.59) | HSD11B1SMN1; SMN2HRH3CHRNB2CHRNA3 | |
| SCHEMBL19111278 | 0.79 | CHRNB2 (0.53) | HSD11B1HRH3CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL25074975 | 0.79 | HSD11B1 (0.46) | HSD11B1SMN1; SMN2HRH3ALDH1A1KDM4E | |
| SCHEMBL20393525 | 0.78 | HSD11B1 (0.71) | HSD11B1SMN1; SMN2KMT2AALDH1A1KDM4E | |
| SCHEMBL18745326 | 0.78 | HPGD (0.45) | HSD11B1SMN1; SMN2HRH3CHRNB2CHRNA3 | |
| SCHEMBL26790447 | 0.78 | HPGD (0.45) | HSD11B1SMN1; SMN2HRH3CHRNB2CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | MDM2, XIAP, ADRM1 | HSD11B1 3041/4885SMN1; SMN2 1059/4885HRH3 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.